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Abstract: 
Introduction: Opioid prescribing and subsequent rates of serious harms have dramatically 
increased in the past two decades, yet there are still significant barriers to reduction of risky 
opioid regimens. This formative evaluation utilized a mixed-methods approach to identify 
barriers and factors that may facilitate the successful implementation of Primary Care-Integrated 
Pain Support (PIPS), a clinical program designed to support the reduction of risky opioid 
regimens while increasing the uptake of non-pharmacologic treatment modalities.  
Methods: Eighteen Department of Veterans Affairs (VA) employees across three sites completed 
a survey consisting of the Organizational Readiness for Implementing Change (ORIC) scale; a 
subset of these individuals (n = 9) then completed a semi-structured qualitative phone interview 
regarding implementing PIPS within the VA. ORIC results were analyzed using descriptive 
statistics while interview transcripts were coded and sorted according to qualitative themes. 
Results: Quantitative analysis based on ORIC indicated high levels of organizational readiness to 
implement PIPS. Interview analysis revealed several salient themes: system-level barriers such 
as tension among various pain management providers; patient-level barriers such as perception 
of support and tension between patient and provider; and facilitating factors of PIPS, such as the 
importance of the clinical pharmacist role. 
Conclusions: While organizational readiness for implementing PIPS appears high, modifications 
to our implementation facilitation strategy (e.g., establishing clinical pharmacists as champions; 
marketing PIPS to leadership as a way to improve VA opioid safety metrics) may improve 
capacity of the sites to implement PIPS successfully. 
Keywords 
Opioid; Chronic pain; Implementation science; formative evaluation; mixed-methods 
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Introduction 
Opioid prescribing, predominantly for chronic pain, quadrupled from 1990-2015; 
meanwhile, rates of serious opioid-related harms have increased.[1] The most catastrophic 
harm—overdose—is now the number one cause of accidental death in the U.S. by a large 
margin.[2] Veterans have approximately twice the rate of opioid overdose compared with non-
veterans.[3] Along with the myriad potential drawbacks of long-term opioid therapy (LTOT), 
mounting evidence suggests it has modest or absent benefit.[1] Moreover, survey-based studies 
of patients describe high levels of ambivalence about LTOT with fears about becoming 
dependent and concerns about waning benefit.[4] 
With mounting evidence for harm and limited benefit of LTOT, both the Centers for 
Disease Control and Prevention and Department of Veterans Affairs/Department of Defense 
(VA/DoD) recently released guidelines for LTOT that stood out as marked departures from 
previous guidelines in that they both recommended avoiding initiation of LTOT.[5, 6] Regarding 
persons currently on LTOT, both strongly recommended tapering or discontinuing opioids if 
harm outweighs benefit. Despite the widespread calls for de-implementing LTOT, patient-
centered methods of tapering or discontinuing LTOT are still needed.[7] One randomized 
controlled trial of a physician assistant led opioid tapering program compared to usual care found 
that the intervention group improved significantly more than the usual care group in self-reported 
pain interference, pain self-efficacy, and prescription opioid problems at 22 weeks.[8] However, 
there was no difference in the decrease in mean opioid dose across groups. In an evaluation of an 
organizational-level implementation intervention to improve pain care quality over four years, 
the proportion of primary care patients on LTOT did not change, despite improvement in several 
other metrics of pain care quality.[9]  
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In our prior qualitative study of barriers and facilitators to reductions in high-dose opioid 
therapy as well as uptake of non-pharmacologic treatment, patients expressed frustration about 
perceived inadequate communication regarding the rationale for pain treatment plans, lack of 
their own and provider knowledge about tapering, and care fragmentation.[10] Other VA-based 
work revealed that patients view the possibility of worsened pain and the specter of the system 
abandoning them as major barriers to initiating tapers.[11] They felt that having access to 
tailored information and timely follow up on treatment plans were important facilitators. 
Providers reported struggling to enhance patients’ motivation to engage with tapers and were 
daunted by the close and frequent follow-up that changes in pain treatment would entail.[12] 
Given all these factors, we developed Primary Care Integrated Pain Support (PIPS), a 
pharmacist-primary care provider collaborative care program to support voluntary reduction of 
high-risk medication regimens and engagement with non-pharmacologic treatment Specific 
components of PIPS include use of an informatics dashboard to identify eligible patients (those 
on ≥ 90 mg morphine equivalent daily dose or combination LTOT and benzodiazepine therapy) 
with an upcoming appointment in primary care; mailing a patient-centered letter inviting patients 
to ask providers about PIPS; a referral template primary care providers use to refer patients to 
PIPS, and a structured intake and follow-up program where a pharmacist works one-on-one with 
patients for up to six months. The design of the clinical intervention was informed in part based 
on a successful model in VA,[13] our prior qualitative work with providers and their patients on 
LTOT for chronic pain that identified the need for better communication among providers and 
patients and improved coordination of pain care, and review of similar evidence-based 
interventions from the literature, including one that decreased opioid use[14] and one that 
decreased benzodiazepine use.[15] To promote uptake of PIPS, we deployed an implementation 
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facilitation approach that has been used successfully in VA primary care clinics.[16] 
Implementation facilitation combines multiple strategies (e.g., engagement of key stakeholders, 
academic detailing, marketing and education) to enable and support individuals, groups, and 
organizations to adopt clinical innovations into routine practice.[17] It relies heavily on iterative 
problem-solving and relationship-building among an expert in the clinical innovation and its 
implementation (i.e., the external facilitator), someone within an organization familiar with its 
structure, policies, and culture who spearheads implementation of the innovation (i.e., an internal 
facilitator), and well-respected persons within the organization who are knowledgeable about the 
innovation and perceived as influential (i.e., champions). Each implementation site, described 
below, has an internal facilitator and 1-2 champions who meet routinely with the external 
facilitator to discuss program implementation. The external facilitator (author WCB) is located at 
VA Connecticut Healthcare System. Herein, we describe the results of a mixed methods 
formative evaluation to guide the development of our implementation facilitation approach to 
foster the adoption of PIPS within the participating VA sites.  
Methods 
Overview of PIPS implementation trial  
The mixed methods formative evaluation occurred in the context of a three-site, hybrid type III 
implementation/effectiveness trial, designed to evaluate our facilitated approach to PIPS 
implementation. The hybrid type III design focuses primarily on establishing the effectiveness of 
the implementation facilitation strategy (e.g., implementation facilitation’s capacity to increase 
the proportion of primary care providers who refer eligible patients to PIPS and proportion of 
these patients who receive PIPS), while observing or gathering information on the clinical 
intervention and related outcomes (e.g., PIPS’ capacity to increase the proportion of patients 
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changed to safer medication regimens and engaged in non-pharmacologic pain 
treatments),.[18].The implementation period will be 18 months in duration and change in clinical 
outcomes, extracted from the electronic health record, will be assessed pre- and post-
implementation using an interrupted time series analysis. Hybrid type III effectiveness-
implementation studies are used when there is insufficient direct evidence for an intervention’s 
effectiveness, yet policy mandates (e.g, VA/DoD guidelines for LTOT), pressing clinical 
problems (e.g. opioid overdose, LTOT ineffectiveness), and indirect support for an intervention 
exist, all conditions present for the PIPS trial. A formative evaluation preceded the actual 
implementation of PIPS to inform the selection and fine-tuning of strategies that comprise the 
implementation facilitation approach used in the study. VA Connecticut’s Investigational 
Review Board (IRB) approved the overall formative evaluation and each site had a separate IRB-
approved protocol for local work. 
Setting 
We are implementing PIPS at the VA Eastern Colorado Healthcare System in Denver, the 
Richard L. Roudebush VA Medical Center in Indianapolis; and the Central Arkansas Veterans 
Healthcare System in Little Rock; all three implementation sites are large VA facilities caring for 
55,000-75,000 veterans in which primary care providers prescribe the majority of LTOT, clinical 
pharmacists are integrated into primary care team-based practice and non-pharmacological pain 
management options are readily available. At the time of study kick off, between 140 and 190 
patients were eligible for PIPS at each site. 
Participants 
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Internal facilitators and champions identified pain care clinical, administrative, and leadership 
stakeholders at their facilities. They approached a mean of 10 individuals per site individuals 
either in person or via email to invite them to participate in the formative evaluation. Potential 
participants received up to two additional reminder emails to schedule an interview, each 10 days 
apart from the prior query. Eighteen individuals agreed to complete the ORIC; 9 also agreed to 
participate in the interview. 
Formative evaluation design, procedures and assessments 
This mixed-methods formative evaluation consisted of (1) a survey about organizational 
readiness for change and (2) semi-structured telephone interviews, each described in detail 
below. Potential participants were identified and invited to participate by the internal facilitator 
at each site. Enrolled participants were first asked to complete the survey, distributed via 
REDCap, and then invited to participate in a semi-structured interview; not all survey 
respondents completed an interview. Interviews were conducted by phone by an experienced 
qualitative researcher (author KMM). 
The survey consisted of the Organizational Readiness for Implementing Change (ORIC) 
instrument,[19] a 10-item survey measure for assessing the shared belief among members of an 
organization that their organization is ready for change – in this case PIPS. Each item is rated 
using a 5-point ordinal scale that ranged from “disagree” to “agree.” It has two subscales: change 
commitment (a shared resolve among organizational members to implement a change) and 
change efficacy (collective capability to implement a change). The total score ranges from 10-50, 
with higher score indicative of greater organizational readiness for change.  Exploratory and 
confirmatory factor analyses, in studies involving a hospital’s readiness to implement use of 
electronic health records and international non-governmental organizations readiness to 
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implement mobile technology systems, revealed two correlated factors with high item loadings 
and good model fit consistent with the theorized subscales.[19] In addition, reliability analysis 
showed high subscale inter-item consistency (ranged from .88 to .92) and inter-rater agreement 
(ranged from .72 to .82).[19]  
In addition, the authors developed a semi-structured interview guide to obtain 
information about factors that might support or hinder PIPS implementation and inform our use 
of the implementation facilitation approach during the trial. We relied upon the Consolidated 
Framework for Implementation Research (CFIR)[20] to develop a series of open-ended 
questions to identify how characteristics of PIPS, site features and processes, and external 
influences could function as implementation facilitators or barriers and inform implementation 
facilitation of PIPS (see Appendix). The guide was used flexibly to follow the flow of 
conversation while addressing all the topics, which included questions both about specific 
components of PIPS and pain treatment issues in general to better appreciate the implementation 
context. Each interview took approximately 30 minutes to complete and all were audio-recorded 
and transcribed verbatim using VA’s centralized transcription service program.  
Data analysis 
We used descriptive statistics to characterize ORIC results. Frequencies and medians 
were calculated in SAS 9.4. Interview transcripts were analyzed qualitatively using procedures 
informed by grounded theory methodology,[21, 22] a systematic approach to deriving qualitative 
themes from textual data. We first conducted open coding in which an investigator identified key 
concepts emerging from the language used by participants and assigned codes (descriptive 
phrases) to segments of text. Atlas.Ti qualitative analysis software (Scientific Software 
Development GmbH, Berlin, Germany) was used to facilitate data coding and sorting. Themes 
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that emerged in the interviews were examined for similarities and differences in perspectives in a 
process known as constant comparison analysis. Subsequently, prominent themes and quotes 
exemplifying each were presented to the research team and refined through discussion.  
Results 
Table 1 describes the participants in the formative evaluation. Eighteen participants completed 
the ORIC and nine (50%) also completed a semi-structured interview. There was variable level 
of participation in the ORIC across sites (Denver=9 respondents, Indianapolis=2 respondents and 
Little Rock=7 respondents). Small numbers precluded formal testing of differences across sites.  
Half of the participants were women (n=9) and half were men. The most common length 
of time that respondents were employed at VA settings was 2-5 years (44.4%), followed by >15 
years (27.8%) (Table 1). Half of persons held administrative or leadership roles, while 27.8% of 
the sample were medical staff that provided direct care. A person may have more than one role in 
the VA so these professional categories are not mutually exclusive. Four of the clinicians 
reported holding administrative/leadership roles. 
Organizational readiness for change 
Survey results are displayed in Table 2. The total median score of 43 indicated a relatively high 
level of readiness for implementing PIPS. The median score on change commitment items was 
slightly higher than change efficacy (22.5 vs. 20.5). Scores were consistent across sites. 
Semi-structured interviews 
Nine participants, representing all sites, completed qualitative interviews; several salient themes 
emerged, some directly related to components of PIPS while others pertained to pain treatment, 
in general. Respondents expressed their perception that inter-provider “turf battles” represent 
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substantial barriers to pain management. In terms of patient barriers, respondents reported their 
perception that fear of abandonment and withdrawal of opioids would be important barriers to 
participation in PIPS. Finally, in terms of facilitators, participants highlighted the importance of 
patient engagement—noting that some patients had done quite well with opioid reductions—and 
most respondents viewed a multidisciplinary team approach as an optimal strategy for providing 
high-quality pain care. 
Turf battles in pain management are a barrier to improving pain care. Several participants spoke 
about tensions between primary care providers and specialty pain clinic providers in terms of 
creating pain management programs that provided broad treatment access for veterans.    
“You know, we have a strong-minded leader of our chronic pain management clinic. We 
have a strong leader leading our primary care program. And getting them on the same 
page and getting them focused on doing what they say they’re going to do have been very 
problematic. I will tell you the honest-to-god truth, there is not a lot of trust and I think 
that in a nutshell is what the problem is.” 
Another participant noted the same struggle at her facility between primary care physicians and 
pain management providers: 
“I think we struggle with the interactions between primary care and our pain program.  
The multi-disciplinary pain program was set up to be a referral option for primary care 
for patients who are high risk or you want to use non-pharmacological treatment. So, it 
was pretty restrictive and so initially it was just for patients who were on so many 
milligrams of opioids or high risk so they set up a lot of restrictions and I would say half 
the patients referred there never came back. A large number of patients never even got 
through it. And so, the providers did not perceive it as that helpful.”   
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
Challenges for patients tapering off opioid medications. Most participants noted that a 
significant barrier to veteran participation was veterans’ fear that they would be tapered off 
opioid medications with little or no support during the process. 
“I guess the biggest challenge patients feel is that they feel alone. You know, if you’re 
gonna recommend a taper because you can tell that the patient’s got some red flags, 
they’re kinda drowning and they don’t know how to save themselves, then those patients 
don’t want to stop typically and so the challenge is, is how to encourage them that, 
“Okay, we’re gonna work together for what you need, not for what you want.” That’s a 
huge challenge, is to try to get buy-in.”   
Another participant concurred with these remarks: 
“The patients want a substitute for what you’re taking away, they want support and just 
someone to acknowledge the fact that it’s not going to be easy and they want to know 
that they’ve got somebody to contact when and if things don’t go right. To me the biggest 
challenge is just getting buy-in from the people who can’t see themselves clearly in the 
mirror that they’ve got a problem, or that the opioids are not helping them have a better 
quality of life, just getting buy-in that there’s a better way.”   
Other participants noted that patients may feel that they are being punished for their current 
opioid use by being referred into a tapering program: 
“The resistance we get is if a patient thinks they are being punished for it. One of the 
worst things that we could possibly do is say to the patient, you’ve violated your pain 
agreement, now you have to come off of it because we’re punishing you.”  
Patient engagement may be helpful in reducing “us” vs. “them” dynamic. Several providers 
remarked on the inherent tension generated by a dynamic where the providers/system are seen as 
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imposing dose reductions on highly ambivalent or even steadfastly resistant patients. One 
provider emphasized the importance of patient engagement in helping alleviate that tension: 
“You know what would be satisfactory is if we started to get a lot more patient 
engagement. That the patients came forward and said, hey, you know, this makes sense, 
this works, I really feel like I can engage in this, and we get a lot more veteran 
empowerment and a lot more patient empowerment to say these are the changes that I 
want to make in my life to maybe get rid of some of these medications or get a very low 
dose of these medications, you know, do as much as I can to eliminate the dangerous 
medications that I’m taking and maybe come up with better plans for pain management. 
So, if we had a successful program which sort of reduced a lot of the disgruntled-ness 
from both the providers and the patient side, and they both were kind of moving together 
as a team with this, that would be success to me.” 
Other providers noted the importance of improvements in quality of life and patient satisfaction: 
“Their activities of daily living and their functional assessments have improved and 
quality of life and patient satisfaction. Actually, quality of life is probably better than 
patient satisfaction, because with patient satisfaction, get back to this politics, we have 
some people that are more satisfied when they get more opioids, or at least in the short 
run, right?” 
Finally, other providers noted the importance of reducing patient deaths due to opioid overdoses: 
“And so I would like to see a decrease in the amount of people on dangerous amounts of 
opiates. So one major concern is people overdosing on these medications, so that would 
be very, fewer of those deaths relating to being on opiates.” 
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Clinical pharmacists play important roles in multi-modal pain management. In considering 
opportunities for multimodal pain treatments, many participants spoke of the centrality of the 
clinical pharmacist on the team. Nearly all participants had worked closely with a clinical 
pharmacist to help manage medications for veterans. 
One participant noted: 
“Our clinical pharmacists are very active and very proactive in doing projects, research, 
working with providers, giving providers reports patients that aren’t being managed, 
especially in the management of all chronic diseases, diabetes, hypertension, heart 
disease. We have clinical pharmacists that are constantly reviewing the medication 
management of these patients and helping us making medical decisions.” 
Another participant concurred: 
“So, we utilize clinical pharmacists as part of the PACT model for quite a while now, 
seven or eight years and it’s been a very positive experience, So, each clinic has a clinical 
pharmacist and they have fairly designated roles, particularly chronic disease 
management so they work with protocols and diabetes management; hypertension, 
thyroid, smoking cessation and they are allowed to adjust medications as part of that 
management. So, I think that’s been, we’ve had a really good experience. They work very 
well embedded in the teams so they’re fairly integrated with the primary care team which 
has been very helpful too.”  
Discussion 
This mixed-methods formative evaluation served the purpose of refining an 
implementation facilitation strategy to promote uptake of PIPS, a collaborative clinical program 
designed to reduce risky medication regimens and increase non-pharmacological pain treatment. 
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The ORIC results revealed an overall high level of readiness for implementing PIPS, with some 
room to further enhance organizational change efficacy. Detailed analysis of the qualitative 
interviews revealed several potential targets on which the implementation facilitation teams 
could focus efforts to improve the likelihood of implementation success.  
By qualitative theme, the first target was participants’ perceptions of system-level 
barriers—particularly concerns that various disciplines struggle to collaborate towards a shared 
mission. This theme has emerged in complementary qualitative studies of VA primary care 
providers’ and nurses’ attitudes about pain care.[23, 24] In response to this challenge, the PIPS 
facilitation team increased efforts to engage facility leadership to emphasize the importance of 
collaboration among various disciplines to reach important VA healthcare system goals. For 
example, the external facilitator worked with the site-based internal facilitators and champions 
about marketing PIPS as a path to help facilities comply with the Opioid Safety Initiative, a 
directive from VA’s Central Office to monitor and improve several metrics of opioid safety.[25] 
The second theme was a patient-level barrier—patients would be too worried about being 
subjected to an involuntary or rapid (or both) opioid taper to engage in PIPS. To address this 
concern, PIPS was designed to place added emphasis on informing patients about evidenced-
based, multi-modal non-pharmacological treatments (e.g., physical therapy,[26] cognitive 
behavioral therapy,[27] yoga,[26] and mindfulness based stress reduction[27]) and how opioid 
tapers would coincide with the introduction of alternative pain management strategies. In 
addition, motivational interviewing[28] serves as a platform in PIPS for clinical pharmacists to 
have collaborative conversations with patients about chronic pain and LTOT and helping them 
commit to safer and more effective multi-modal pain care. To this end,  the clinical teams across 
sites involved in PIPS delivery participate in monthly community of practice calls in which they 
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discuss multi-modal pain care options, address challenging clinical situations (e.g. difficult 
tapers, less motivated patients), fine-tune communication skills, and identify new tools to 
promote high-quality pain care (e.g. use of an importance/confidence ruler, implemented by 
pharmacists, to aid in the motivational interviewing process). Finally, presuming patients will be 
successfully tapered and experience pain relief from nonpharmacological treatments promoted 
through PIPS, the facilitation team members will seek guidance from these patients about how 
best to market the program to others who may be reluctant to engage in it.  
In addition, the qualitative analysis identified the important  role of the clinical pharmacy 
specialist as a critical piece of the PIPS clinical program. In most VA facilities, including the 
three implementation sites, clinical pharmacy specialists are already integrated into primary care, 
performing chronic disease management one-on-one with patients. Considering the focus on 
medication safety, participants saw pharmacist involvement as a significant facilitator to PIPS 
implementation success. Hence, clinical pharmacy specialists are members of our 
implementation teams at each of the sites, and we intend to leverage their vital primary care role 
to remedy the problem of uncoordinated pain care silos mentioned in the semi-structured 
interviews. Of note, the pharmacists delivering PIPS at the three sites have experience with 
chronic pain management, so the goal of promoting and encouraging non-pharmacologic 
treatment modalities in conjunction with medication safety messaging was not a barrier. In fact, 
given their pain care expertise, they will serve as PIPS champions at each site and be directly 
involved in marketing PIPS to providers and educating staff about multi-modal pain 
management. Pharmacists without chronic pain management experience would likely need 
additional training in pain management approaches to feel comfortable and confident in this role.  
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Our study’s findings should be interpreted in the context of the study’s limitations. First, 
the study was performed exclusively in VA facilities and thus may not be generalizable outside 
the VA. That said, while non-integrated systems in community settings may have more 
substantive system-level barriers to implementing PIPS or a program like it, the perceived 
patient-level barriers reported by participants may be equally relevant in non-VA settings. 
Second, with a small sample size of 18 participants, only half of whom completed qualitative 
interviews, we may not have captured all the relevant, important perspectives that could impact 
successful implementation of PIPS. In particular, the participation of only two persons at the 
Indianapolis site may serve as a flag for future barriers to PIPS implementation. Furthermore, the 
high proportion of individuals with leadership roles in our sample may have obscured some of 
the barriers associated with day-to-day clinical issues and may have led to inflated scores on the 
ORIC. Nonetheless, several respondents reporting leadership roles also work in the clinics and 
thus likely have familiarity with the day-to-day challenges of pain care. 
 This formative evaluation guided modifications to an implementation facilitation strategy 
that will be used to promote uptake of a collaborative care program to improve quality and safety 
of chronic pain care. While organizational readiness for implementing PIPS appears high, the 
modifications to our implementation facilitation strategy based on this formative evaluation may 
further enhance the organizational readiness of the sites by bolstering capacity to put PIPS in 
place. Future research will focus on measuring what aspects of implementation facilitation were 
used during the implementation phase of the PIPS trial, which components of PIPS were 
implemented at the sites, and what effect PIPS had on patient-level outcomes (e.g., successful 
transition to safer medication regimens, utilization of non-pharmacological pain treatment 
modalities).  
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Table 1: Description of survey participants (N=18) 
Years in VA 
 
N %  Position(s) 
 
N % 
<2 2 11.1  Administrator/ 
leadership 
9 50.0 
2-5 8 44.4  PCP (Physician, NP, PA) 5 27.8 
6-10 1 5.6  Pharmacist 2 11.1 
11-15 2 11.1  Psychologist/Psychiatrist 3 16.7 
>15 5 27.8  Other/not specified 3 16.7 
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Table 2: Organizational Readiness for Implementing Change (ORIC) instrument 
Domain Survey Item Median 
Change commitment People who work here are motivated to 
implement PIPS (Q9). 
5.00 
People who work here want to implement 
PIPS (Q5). 
5.00 
People who work here will do whatever it 
takes to implement PIPS (Q3). 
4.00 
People who work here are committed to 
implementing PIPS (Q1). 
4.00 
People who work here are determined to 
implement PIPS (Q7). 
4.00 
Change efficacy People who work here feel confident that 
they can keep track of progress in 
implementing PIPS (Q2). 
5.00 
People who work here feel confident that 
the organization can support people as 
they adjust to PIPS (Q4).   
4.00 
People who work here feel confident that 
they can keep the momentum going in 
implementing PIPS (Q6). 
4.00 
People who work here feel confident that 
they can manage the politics of 
implementing PIPS (Q10). 
4.00 
People who work here feel confident that 
they can coordinate tasks so that PIPS 
implementation goes smoothly (Q8). 
4.00 
Change Commitment  
Subscore 
SUM OF Q1, Q3, Q5, Q7, Q9 22.50 
Change Efficacy 
Subscore 
 
SUM OF Q2, Q4, Q6, Q8, Q10 20.50 
Total Score SUM OF ALL 43.00 
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Appendix: Semi-structured Interview Guide 
Introduction/Orientation 
Thank you for agreeing to be interviewed about the plan to implement a new chronic pain management 
program at [name of VA].  The program is called Primary care-Integrated Pain Support or PIPS. The PIPS 
program uses a care management strategy in an attempt to decrease the proportion of Veterans on 
high-risk medication regimens for chronic pain, while increasing the proportion of Veterans treated with 
non-pharmacologic pain treatment modalities (NPMs).   
As you are well aware, chronic pain care and opioid prescribing have received a lot of attention within 
and outside of the VA healthcare system.  The VA Opioid Safety Initiative (OSI) has set up expectations 
for facilities and PACTS/PCPs to provide safer and more effective pain treatment for Veterans.  To date, 
much of the OSI’s emphasis has been on monitoring practices (urine drug tests, querying the 
prescription drug monitoring database) and patient education (signed informed consent).  Less attention 
has been given to implementing new programs designed to help patients transition to safer medication 
regimens and make greater use of non-pharmacologic pain treatment modalities (NPM) such as 
cognitive behavioral therapy for pain, yoga, acupuncture, and meditation.  
The PIPS program will facilitate collaboration between primary care physicians and pharmacists.  PIPS 
has several components including:  
1. Mailing a letter to eligible Veterans in advance of a routine primary care appointment that 
explains the nature of and rationale for PIPS and encourages Veterans to speak about it with 
their primary care provider.  
2. During the routine appointment, the primary care provider guides the Veteran through a brief, 
templated pharmacy consult request.   
3. Cued by the consult, the pharmacist has up to two weeks to arrange an initial meeting with the 
Veteran in which the pharmacist will build rapport, review preferences, start the taper plan, and 
set a schedule for follow-up. The pharmacist will use a protocol for dose tapering that will 
specify dose and number of pills supplied at each 2-week interval and use clinical judgment to 
alter the schedule as needed.  Primary care providers will electronically s ign prescriptions. 
4. Pharmacist follow-up will match the Veterans’ needs, and will include one session per week for 
the first 4 weeks followed by biweekly sessions for 12 weeks. Veterans may receive support 
from PIPS pharmacists for up to 6 months. Follow-up sessions (a blend of telephone or face-to-
face meetings) will involve monitoring of (a) progress with medication changes, (b) safety, and 
(c) engagement with NPM. Primary care providers will be added as additional signers to 
pharmacist notes indicating the progress of tapers and expected date of patient’s discharge 
from PIPS, ensuring seamless transition.  In addition, the pharmacist will submit referrals for the 
patient’s preferred NPM, track their attendance, and address barriers to NPM adherence. In 
addition, pharmacists will have the ready assistance of RN care managers.  
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Interview:  I’d like to ask you a few questions about plans to implement PIPS at [name of VA].  
 
CFIR Construct Questions Probes 
First, I would like to ask you a few questions to help me understand your role in your facility and in 
providing pain care at your facility. 
Role in Facility Tell me a little bit about your experience 
working here in the VA.  
 
How many years have you 
worked at VA? 
 
Which service line are you a 
part of?  
 
What are your primary job 
responsibilities?  
Now let’s talk a little bit about pain care at your facility.  
 
Inner Setting - Compatibility Describe your facility’s organizational 
stance (or mindset) toward pain?  
 
How much have you heard about multi-
modal pain care in your facility?  
 
Are you aware of efforts at your facility 
to reduce high dose opioids or to 
increase uptake of non-pharmaceutical 
pain treatments?  
If you have a pain strategy, is 
it facility-based or 
coordinated across the VISN?  
 
 
Process - Champions Is there an individual or a group of 
individuals who would be considered 
pain champions within your facility or 
VISN?   
Who would be effective in 
championing PIPS at your 
facility? 
 
What would this 
individual/champion need to 
do to help integrate PIPS into 
the practice? 
Process - Opinion Leaders Who are the key influential individuals 
to get on board with implementing a 
new pain management program like 
PIPS? 
How could they be 
influential? 
Characteristics of Individuals 
– Self-Efficacy 
(This question is for PCPs) 
Please describe your experience 
collaborating with clinical pharmacy 
specialists as part of patient care for 
other conditions.  
 
How comfortable are you 
referring your patients to 
clinical pharmacy specialists? 
 
Have you collaborated with 
clinical pharmacists to taper 
patient medication? If so, 
what was that experience 
like?   
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Characteristics of Individuals 
– Self-Efficacy  
 
(This question is for Clinical 
Pharmacists only) 
Please describe your experience 
collaborating with PCPs and/or MH 
providers as part of patient care. 
In general? 
 
In the context of pain 
management? 
 
Where medication tapering 
is part of patient care? 
Characteristics of Individuals 
– Self-Efficacy  
 
(This question is for Mental 
Health Providers only) 
Please describe your experience 
collaborating with primary care as part 
of patient care. 
  
 
Have you collaborated with 
primary care where a patient 
has been prescribed both 
opioids and benzos? If so, 
what was that experience 
like?  (ONLY ASK 
PSYCHIATRISTS THIS 
QUESTION) 
 
Have you ever worked with 
clinical pharmacists to taper 
patient medication? If so, 
what was that experience 
like?  (ONLY ASK 
PSYCHIATRISTS THIS 
QUESTION) 
Now let’s talk about discussions you might have with your patients relating to medication tapering 
and discontinuation.   
 
 How comfortable are you discussing 
medication tapers with your patients? 
 
 
 Would you be willing to check a box in a 
consult that says you had a conversation 
with the patient about medication 
tapering? 
 
 
Characteristics of Individuals 
– Individual Identification 
with Organization 
Do you have experience with 
motivational interviewing?  
Have you ever engaged in 
motivational interviewing 
with patients? Do you feel 
like your facility supports 
motivational interviewing as 
a means by which to 
motivate behavioral change 
in patients? 
Next let’s talk about the PIPS clinical program. 
 
Inner Setting - Access to 
Knowledge & Information  
 
We described the PIPS program a little 
earlier – is that the first time you had 
heard of it? If you were aware of PIPS 
What other ways would be 
useful to inform providers 
and patients about PIPS?   
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
Characteristics of Individuals 
- Knowledge and Beliefs 
about the Intervention 
before today, where did you hear about 
it? What have you heard? 
Intervention Characteristics - 
Evidence Strength & Quality 
What kind of information or evidence 
would be useful to you about 
how/whether the PIPS program works? 
Information from your own 
experience, knowledge of 
consensus guidelines, 
published literature, or other 
sources? From co-workers? 
From supervisors? 
 
Is there additional/other 
information or evidence that 
you would find useful? 
 What would success look like in the PIPS 
program? What kind of outcome would 
you consider a success?  
 
Intervention Characteristics -
Relative Advantage 
What aspects of PIPS seem useful for 
Veterans? Providers?   
What else about PIPS seems 
attractive?  
1. One on one counseling 
with pharmacist   
2. Patients learn about and 
participate in NPMs   
Outer Setting - Patient 
Needs & Resources 
 
Outer Setting – Available 
Resources 
What barriers will patients face to 
participating in the PIPS program? 
External (e.g., transportation costs, 
time)? Internal (e.g., lack of staff)? 
 
 
Outer Setting - External 
Policy & Incentives 
How would PIPS fit into your VA’s efforts 
to comply with the OSI? 
How well does PIPS fit with 
other initiatives at your VA?  
Which ones? 
Inner Setting - Networks & 
Communications 
How has the staff been informed about 
PI S at your facility? 
 
How else should we get the word out 
about PIPS? 
How do you work together? 
 
 
Meetings? 
Personal contact? 
Distributed materials? 
E-mail communications? 
Other? 
Characteristics of Individuals 
– Individual Stage of Change  
Is there a specific type of patient with 
pain that you think would definitely be 
appropriate for the PIPS program? Not 
appropriate for the PIPS program?  
How do you decide which 
patients might be open to 
hearing about a program like 
PIPS? 
Inner Characteristics - 
Adaptability 
Are there any things about PIPS that you 
think should be changed or added to it?  
If yes, what are they? 
Do you think other people 
might suggest changes to 
PIPS?  If yes, how so? 
Finally, let’s talk about what kind of information you would like regarding implementation of PIPS as it 
relates to your patients.  
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Inner Setting - Access to 
Knowledge & Information  
What kind of information or feedback 
would you want/need about your 
patients who are participating in PIPS?  
How would you like that information 
provided/communicated to you? 
Weekly treatment notes with 
you as a cosigner? 
A single note with the 
patient stating when the 
patient entered treatment 
and if they 
completed/dropped out? 
Inner Setting - Goals & 
Feedback  
What feedback (if any) would you like 
related to PIPS? (e.g., referral reports, % 
of patients completing the program)  
 
What data should be 
reported?  
 
# letters sent? 
# signed consults completed? 
# Veterans meeting with PIPS 
pharmacist 
# PIPS meetings completed 
per Veteran 
 
Conclusion.  Thank you so much for participating in this interview. 
 
 Is there anything that we haven’t asked 
that you think might be important for us 
to know?  
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Highlights 
 Stakeholders support the intervention but organizational barriers persist. 
 Motivating patients to agree to opioid tapers was a prevalent concern.  
 Pharmacists were viewed as ideal collaborators with patients and primary care physicians.  
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